FER tyrosine kinase (FER) overexpression mediates resistance to quinacrine through EGF-dependent activation of NF-κB

Proceedings of the National Academy of Sciences of the United States of America

Volumn 108, Issue 19, 2011, Pages 7968-7973

  Guo, Canhui ^a   Stark, George R ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MEPACRINE; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE FER;

ANTIBIOTIC RESISTANCE; ARTICLE; CANCER CELL; CANCER RESISTANCE; CELL KILLING; CELL MUTANT; CELL SURVIVAL; ENZYME ACTIVATION; ENZYME INHIBITION; GENE CONSTRUCT; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOBLOTTING; IMMUNOPRECIPITATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PHOSPHORYLATION; RECEPTOR UPREGULATION; VIRUS INFECTION;

CELL LINE, TUMOR; CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; EPIDERMAL GROWTH FACTOR; GENE EXPRESSION; HUMANS; NF-KAPPA B; PROTO-ONCOGENE PROTEINS C-AKT; QUINACRINE; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; UP-REGULATION;

EID: 79956344228     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1105369108     Document Type: Article

References (41)

1. Wallace DJ (1989) The use of quinacrine (Atabrine) in rheumatic diseases: A reexamination. Semin Arthritis Rheum 18:282-296.
2. Toubi E, et al. (2006) The reduction of serum B-lymphocyte activating factor levels following quinacrine add-on therapy in systemic lupus erythematosus. Scand J Immunol 63:299-303.
3. Sun S, Rao NL, Venable J, Thurmond R, Karlsson L (2007) TLR7/9 antagonists as therapeutics for immune-mediated inflammatory disorders. Inflamm Allergy Drug Targets 6:223-235.
4. Gurova KV, et al. (2005) Small molecules that reactivate p53 in renal cell carcinoma reveal a NF-kappaB-dependent mechanism of p53 suppression in tumors. Proc Natl Acad Sci USA 102:17448-17453. (Pubitemid 41740886)
5. Guo C, et al. (2009) 9-Aminoacridine-based anticancer drugs target the PI3K/AKT/ mTOR, NF-kappaB and p53 pathways. Oncogene 28:1151-1161.
6. Lu T, et al. (2009) Validation-based insertional mutagenesis identifies lysine demethylase FBXL11 as a negative regulator of NFkappaB. Proc Natl Acad Sci USA 106:16339-16344.
7. De S, Cipriano R, Jackson MW, Stark GR (2009) Overexpression of kinesins mediates docetaxel resistance in breast cancer cells. Cancer Res 69:8035-8042.
8. Hayden MS, Ghosh S (2004) Signaling to NF-kappaB. Genes Dev 18:2195-2224.
9. Biswas DK, Cruz AP, Gansberger E, Pardee AB (2000) Epidermal growth factor-induced nuclear factor kappa B activation: A major pathway of cell-cycle progression in estrogen-receptor negative breast cancer cells. Proc Natl Acad Sci USA 97:8542-8547. (Pubitemid 30639709)
10. Biswas DK, Iglehart JD (2006) Linkage between EGFR family receptors and nuclear factor kappaB (NF-kappaB) signaling in breast cancer. J Cell Physiol 209:645-652. (Pubitemid 44665682)
11. Le Page C, Koumakpayi IH, Lessard L, Mes-Masson AM, Saad F (2005) EGFR and Her-2 regulate the constitutive activation of NF-kappaB in PC-3 prostate cancer cells. Prostate 65:130-140. (Pubitemid 41362280)
12. Okamoto I (2010) Epidermal growth factor receptor in relation to tumor development: EGFR-targeted anticancer therapy. FEBS J 277:309-315.
13. Kim L, Wong TW (1998) Growth factor-dependent phosphorylation of the actin-binding protein cortactin is mediated by the cytoplasmic tyrosine kinase FER. J Biol Chem 273:23542-23548. (Pubitemid 28417547)
14. Kim L, Wong TW (1995) The cytoplasmic tyrosine kinase FER is associated with the catenin-like substrate pp120 and is activated by growth factors. Mol Cell Biol 15:4553-4561.
15. Penhallow RC, Class K, Sonoda H, Bolen JB, Rowley RB (1995) Temporal activation of nontransmembrane protein-tyrosine kinases following mast cell Fc epsilon RI engagement. J Biol Chem 270:23362-23365.
16. Greer P (2002) Closing in on the biological functions of Fps/Fes and fer. Nat Rev Mol Cell Biol 3:278-289.
17. Taler M, et al. (2003) Fer is a downstream effector of insulin and mediates the activation of signal transducer and activator of transcription 3 in myogenic cells. Mol Endocrinol 17:1580-1592. (Pubitemid 36930472)
18. Zoubeidi A, et al. (2009) The Fer tyrosine kinase cooperates with interleukin-6 to activate signal transducer and activator of transcription 3 and promote human prostate cancer cell growth. Mol Cancer Res 7:142-155.
19. Iwanishi M (2003) Overexpression of Fer increases the association of tyrosine-phosphorylated IRS-1 with P85 phosphatidylinositol kinase via SH2 domain of Fer in transfected cells. Biochem Biophys Res Commun 311:780-785.
20. Iwanishi M, Czech MP, Cherniack AD (2000) The protein-tyrosine kinase fer associates with signaling complexes containing insulin receptor substrate-1 and phosphatidylinositol 3- kinase. J Biol Chem 275:38995-39000. (Pubitemid 32058911)
21. Luo JL, Kamata H, Karin M (2005) IKK/NF-kappaB signaling: Balancing life and death - a new approach to cancer therapy. J Clin Invest 115:2625-2632. (Pubitemid 41434385)
22. Jani TS, DeVecchio J, Mazumdar T, Agyeman A, Houghton JA (2010) Inhibition of NF- κB signaling by quinacrine is cytotoxic to human colon carcinoma cell lines and is synergistic in combination with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) or oxaliplatin. J Biol Chem 285:19162-19172.
23. Karin M, Greten FR (2005) NF-kappaB: Linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 5:749-759. (Pubitemid 41400849)
24. Baldwin AS, Jr. (1996) The NF-kappa B and I kappa B proteins: New discoveries and insights. Annu Rev Immunol 14:649-683.
25. Nakanishi C, Toi M (2005) Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer 5:297-309. (Pubitemid 40488635)
26. Ozes ON, et al. (1999) NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature 401:82-85.
27. Habib AA, et al. (2001) The epidermal growth factor receptor engages receptor interacting protein and nuclear factor-kappa B (NF-kappa B)-inducing kinase to activate NF-kappa B. Identification of a novel receptor-tyrosine kinase signalosome. J Biol Chem 276:8865-8874.
28. Sethi G, Ahn KS, Chaturvedi MM, Aggarwal BB (2007) Epidermal growth factor (EGF) activates nuclear factor-kappaB through IkappaBalpha kinase-independent but EGF receptor-kinase dependent tyrosine 42 phosphorylation of IkappaBalpha. Oncogene 26:7324-7332. (Pubitemid 350115978)
29. Salem Y, et al. (2005) Fer kinase sustains the activation level of ERK1/2 and increases the production of VEGF in hypoxic cells. Cell Signal 17:341-353. (Pubitemid 39574695)
30. Sakurai H, Chiba H, Miyoshi H, Sugita T, Toriumi W (1999) IkappaB kinases phosphorylate NF-kappaB p65 subunit on serine 536 in the transactivation domain. J Biol Chem 274: 30353-30356.
31. Balin-Gauthier D, et al. (2006) In vivo and in vitro antitumor activity of oxaliplatin in combination with cetuximab in human colorectal tumor cell lines expressing different level of EGFR. Cancer Chemother Pharmacol 57:709-718.
32. Luqmani YA (2005) Mechanisms of drug resistance in cancer chemotherapy. Med Princ Pract 14(Suppl 1):35-48.
33. Gottesman MM (2002) Mechanisms of cancer drug resistance. Annu Rev Med 53: 615-627.
34. Allard P, et al. (2000) Links between Fer tyrosine kinase expression levels and prostate cell proliferation. Mol Cell Endocrinol 159:63-77. (Pubitemid 30067641)
35. Pasder O, Salem Y, Yaffe E, Shpungin S, Nir U (2007) FER as a novel target for cancer therapy. Drugs of the Future 32:61-70. (Pubitemid 46682282)
36. Li H, et al. (2009) Identification of tyrosine-phosphorylated proteins associated with metastasis and functional analysis of FER in human hepatocellular carcinoma cells. BMC Cancer 9:366-382.
37. Paulson R, Jackson J, Immergluck K, Bishop JM (1997) The DFer gene of Drosophila melanogaster encodes two membrane-associated proteins that can both transform vertebrate cells. Oncogene 14:641-652. (Pubitemid 27095855)
38. Mitsudomi T, Yatabe Y (2010) Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer. FEBS J 277:301-308.
39. Merkhofer EC, Cogswell P, Baldwin AS (2010) Her2 activates NF-kappaB and induces invasion through the canonical pathway involving IKKalpha. Oncogene 29:1238-1248.
40. Cheon H, Stark GR (2009) Unphosphorylated STAT1 prolongs the expression of interferon-induced immune regulatory genes. Proc Natl Acad Sci USA 106:9373-9378.
41. Gasparian AV, et al. (2009) Targeting transcription factor NFkappaB: Comparative analysis of proteasome and IKK inhibitors. Cell Cycle 8:1559-1566.